Leuprolide acetate 7.5mg; depot susp for IM inj; preservative-free. Store between 20° to 25°C (68° to 77°F); excursions permitted to 15°C to 30°C (59°F to86°F). Give as single IM inj into gluteal area ...

Leuprolide acetate 22.5mg; depot susp for IM inj; preservative-free. Store between 20° to 25°C (68° to 77°F); excursions permitted to 15°C to 30°C (59°F to86°F). Give as single IM inj into gluteal ...

Cipla is introducing leuprolide acetate injection depot, 22.5 mg, which is the generic of AbbVie’s Lupron Depot. It is indicated for palliative treatment of advanced prostate cancer. Leuprolide ...

Abbott announced that the US Food and Drug Administration (FDA) has approved two new strengths for three-month administration of Lupron Depot-PED (leuprolide acetate for depot suspension) for the ...

The FINANCIAL — Abbott Park, Illinois — Abbott announced today that the U.S. Food and Drug Administration (FDA) has approved a new 45 mg for six-month administration formulation of Lupron Depot® ...

Cipla has launched Leuprolide Acetate Injection Depot 22.5mg. The product was approved by the United States Food and Drug Administration (US FDA) based on a New Drug Application (NDA) submitted under ...

Cipla Limited and its wholly owned subsidiary Cipla USA Inc. , today announced the launch of Leuprolide Acetate Injection Depot 22.5mg. The product was approved by the United States Food and Drug ...

Cipla Limited (BSE: 500087) (NSE: CIPLA EQ) and its wholly owned subsidiary Cipla USA Inc. (hereafter referred to as 'Cipla'), today announced the launch of Leuprolide Acetate Injection Depot 22.5mg.